Published in Curr Cancer Drug Targets on September 01, 2012
Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids (2014) 1.81
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 1.50
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget (2013) 1.26
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res (2013) 1.23
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget (2015) 1.08
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget (2014) 1.07
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 1.06
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One (2014) 1.01
In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One (2014) 1.00
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget (2015) 0.91
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia (2015) 0.89
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget (2015) 0.86
miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics (2013) 0.83
Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv (2013) 0.83
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget (2015) 0.83
Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. J R Soc Interface (2013) 0.82
MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med (2015) 0.81
miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget (2016) 0.79
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. Biomed Res Int (2016) 0.79
Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci Rep (2015) 0.78
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. Mol Ther Nucleic Acids (2016) 0.78
Role of micro-RNAs in drug resistance of multiple myeloma. Oncotarget (2016) 0.77
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci (2016) 0.76
A systematic review on in vitro 3D bone metastases models: A new horizon to recapitulate the native clinical scenario? Oncotarget (2016) 0.76
An in vitro 3D bone metastasis model by using a human bone tissue culture and human sex-related cancer cells. Oncotarget (2016) 0.75
Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma. RNA Biol (2015) 0.75
Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors. Genes (Basel) (2016) 0.75
Towards Stratified Medicine in Plasma Cell Myeloma. Int J Mol Sci (2016) 0.75
miR-29b: a new demethylator in multiple myeloma. Cell Cycle (2013) 0.75
Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. Sci Rep (2016) 0.75
Oncogenic role of microRNA-20a in human multiple myeloma. Onco Targets Ther (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The functions of animal microRNAs. Nature (2004) 64.85
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Getting to the root of miRNA-mediated gene silencing. Cell (2008) 7.17
MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell (2008) 6.58
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73
GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay. Nat Struct Mol Biol (2008) 5.57
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood (2007) 5.14
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
Deadenylation is a widespread effect of miRNA regulation. RNA (2008) 3.98
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
Transcriptional control of gene expression by microRNAs. Cell (2010) 3.05
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Regression of murine lung tumors by the let-7 microRNA. Oncogene (2009) 2.83
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
The promise of microRNA replacement therapy. Cancer Res (2010) 2.68
Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res (2007) 2.65
Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood (2009) 2.46
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood (2009) 2.08
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A (2010) 1.78
miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol (2011) 1.78
Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis (2010) 1.62
Cancer complexity slows quest for cure. Nature (2008) 1.47
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
MicroRNAs as a potential magic bullet in cancer. Future Oncol (2006) 1.35
MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm (2011) 1.25
Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol (2005) 1.16
MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct (2011) 1.10
Deregulated microRNAs in multiple myeloma. Cancer (2011) 1.05
A systematic screen for micro-RNAs regulating the canonical Wnt pathway. PLoS One (2011) 1.00
Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma (2009) 0.98
MicroRNAs: New Players in Multiple Myeloma. Front Genet (2011) 0.91
RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol (2009) 0.87
Expression and mutation status of candidate kinases in multiple myeloma. Leukemia (2007) 0.87
MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol (2010) 0.86
Oligonucleotide delivery in cancer therapy. Expert Opin Drug Deliv (2010) 0.83
Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica (2010) 0.82
Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules (2009) 0.82
MicroRNA-122 might be a double-edged sword in hepatocellular carcinoma. Hepatology (2009) 0.80
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med (2001) 5.66
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1991) 3.69
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A (1998) 2.76
EFA6, a sec7 domain-containing exchange factor for ARF6, coordinates membrane recycling and actin cytoskeleton organization. EMBO J (1999) 2.63
Differences in abuse reported by female and male Canadian medical students. CMAJ (1994) 2.41
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood (1997) 2.31
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Health risks posed by use of Di-2-ethylhexyl phthalate (DEHP) in PVC medical devices: a critical review. Am J Ind Med (2001) 2.00
Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. J Natl Cancer Inst (1982) 1.93
Age-related loss of axospinous synapses formed by two afferent systems in the rat dentate gyrus as revealed by the unbiased stereological dissector technique. Hippocampus (1992) 1.85
IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease. J Pediatr (1999) 1.82
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia (2009) 1.80
One-year follow-up after laparoscopic Heller-Dor operation for esophageal achalasia. Surg Endosc (1997) 1.78
Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ (2008) 1.77
Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health (1998) 1.73
The rates of false-positive lumbar discography in select patients without low back symptoms. Spine (Phila Pa 1976) (2000) 1.71
A protein disulfide oxidoreductase from the archaeon Pyrococcus furiosus contains two thioredoxin fold units. Nat Struct Biol (1998) 1.70
An autonomously replicating transforming vector for Sulfolobus solfataricus. J Bacteriol (1998) 1.69
Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology (1999) 1.65
Crystal structure of the beta-glycosidase from the hyperthermophilic archeon Sulfolobus solfataricus: resilience as a key factor in thermostability. J Mol Biol (1997) 1.59
Rectal chlamydia--a reservoir of undiagnosed infection in men who have sex with men. Sex Transm Infect (2009) 1.59
The crystal structure of a hyper-thermophilic carboxylesterase from the archaeon Archaeoglobus fulgidus. J Mol Biol (2001) 1.58
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity (2001) 1.56
Preoperative staging of primary breast cancer. A multicentric study. Cancer (1988) 1.56
FLASH is required for histone transcription and S-phase progression. Proc Natl Acad Sci U S A (2006) 1.56
Surface staining on the villus of lactase protein and lactase activity in adult-type hypolactasia. Gastroenterology (1993) 1.53
Incidence of metabolic syndrome among night-shift healthcare workers. Occup Environ Med (2009) 1.53
Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. Diabetologia (2013) 1.51
Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene (1993) 1.51
A technique to detect reduced mechanical stability of red cell membranes: relevance to elliptocytic disorders. Blood (1982) 1.49
Restoration of normal membrane stability to unstable protein 4.1-deficient erythrocyte membranes by incorporation of purified protein 4.1. J Clin Invest (1986) 1.47
Isolation and sequencing of a new beta-galactosidase-encoding archaebacterial gene. Gene (1990) 1.47
A DNA polymerase from the archaeon Sulfolobus solfataricus shows sequence similarity to family B DNA polymerases. Nucleic Acids Res (1992) 1.46
Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant (2015) 1.46
Epidemic of malaria in north-eastern Kenya. Lancet (1998) 1.45
Potassium depletion and salt sensitivity in essential hypertension. J Clin Endocrinol Metab (2001) 1.44
Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem (2000) 1.43
Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis (2005) 1.42
Magnetic resonance findings and ophthalmologic abnormalities are correlated in patients with neurofibromatosis type 1 (NF1). Am J Med Genet (2000) 1.42
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Deoxycytidylate aminohydrolase. I. Preparation and properties of the homogeneous enzyme. Biochemistry (1967) 1.38
Pinna haematomas of the conchal bowl. Clin Otolaryngol (2007) 1.37
The use of quinidine in cardioversion. Am J Cardiol (1967) 1.37
Thermostable beta-galactosidase from the archaebacterium Sulfolobus solfataricus. Purification and properties. Eur J Biochem (1990) 1.35
Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood (1988) 1.34
BIOTIN AND PROPIONYL CARBOXYLASE. Proc Natl Acad Sci U S A (1960) 1.32
Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene (1997) 1.31
Systemic acute-phase response after laparoscopic and open cholecystectomy. Surg Endosc (2001) 1.30
Risk and prevention of type 2 diabetes in women with gestational diabetes. Diabetes Care (1998) 1.29
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res (2000) 1.28
Structural and functional characterization of the promoter regions of the NFKB2 gene. Nucleic Acids Res (1995) 1.28
Structural synaptic correlate of long-term potentiation: formation of axospinous synapses with multiple, completely partitioned transmission zones. Hippocampus (1993) 1.27
Phenotypic drift of metastatic and cell-surface properties of mammary adenocarcinoma cell clones during growth in vitro. Int J Cancer (1981) 1.26
Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood (1991) 1.26
A snapshot of a transition state analogue of a novel thermophilic esterase belonging to the subfamily of mammalian hormone-sensitive lipase. J Mol Biol (2000) 1.25
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene (2001) 1.25
The lactase persistence/non-persistence polymorphism is controlled by a cis-acting element. Hum Mol Genet (1995) 1.24
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood (1994) 1.23
Stabilization of Enzymes against Thermal Stress and Freeze-Drying by Mannosylglycerate. Appl Environ Microbiol (1997) 1.23
Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J Chemother (2001) 1.22
Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes (2000) 1.22
Lysyl hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity. J Biol Chem (2000) 1.22
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia (2013) 1.21
Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol (2007) 1.21
Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol (1995) 1.21
Contribution of the band 3-ankyrin interaction to erythrocyte membrane mechanical stability. Blood (1991) 1.21
An Lrp-like protein of the hyperthermophilic archaeon Sulfolobus solfataricus which binds to its own promoter. J Bacteriol (1999) 1.20
Effects of ultrasound guidance on the minimum effective anaesthetic volume required to block the femoral nerve. Br J Anaesth (2007) 1.20
Esophageal achalasia: laparoscopic versus conventional open Heller-Dor operation. Am J Surg (1995) 1.19
Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat (2006) 1.18
Identification and molecular characterization of the first alpha -xylosidase from an archaeon. J Biol Chem (2000) 1.17
Synthesis, structure, and antitumor activity of a novel tetranuclear titanium complex. J Med Chem (2000) 1.17
Metallic stents in malignant biliary obstruction: results of a multicenter European study of 240 patients. J Vasc Interv Radiol (1994) 1.17
Laparoscopic versus open cholecystectomy. An analysis of clinical and financial aspects. Panminerva Med (2001) 1.16
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol (2008) 1.16
Reversible diffusion MRI abnormalities and transient mutism after liver transplantation. Neurology (2004) 1.16
Deoxycytidylate aminohydrolase. II. Kinetic properties. The activatory effect of deoxycytidine triphosphate and the inhibitory effect of deoxythymidine triphosphate. Biochemistry (1967) 1.16
Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol (2001) 1.15
Visual feedback has differential effects on reaching movements in Parkinson's and Alzheimer's disease. Brain Res (2000) 1.15
Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death Differ (2007) 1.15
Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect (2011) 1.15
A novel archaebacterial NAD+-dependent alcohol dehydrogenase. Purification and properties. Eur J Biochem (1987) 1.15
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia (2007) 1.14
Endometrial polyps during menopause: characterization and significance. Acta Obstet Gynecol Scand (1999) 1.14
Thermostable NAD(+)-dependent alcohol dehydrogenase from Sulfolobus solfataricus: gene and protein sequence determination and relationship to other alcohol dehydrogenases. Biochemistry (1992) 1.14
Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene (2012) 1.13
Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system. Neurosci Lett (2000) 1.13